Invitae, the leading medical genetics company, has recently received court approval for a five-month bankruptcy sale. This decision comes as the company seeks to restructure and address its financial challenges.
The San Francisco-based company had filed for Chapter 11 bankruptcy protection in January, citing difficulties in generating sufficient revenue to sustain its operations. Invitae focuses on providing comprehensive genetic testing services to support physicians and patients in making informed healthcare decisions.
